|
Impact of nirogacestat on pain, a key symptom in patients with desmoid tumors (DT): Results from the phase 3 DeFi study. |
| |
Winette T.A. Van Der Graaf |
Consulting or Advisory Role - Agenus (Inst); Bayer (I); Novartis (I); PTC Therapeutics (Inst); SpringWorks Therapeutics (Inst) |
Research Funding - Lilly (Inst) |
| |
|
Honoraria - Flatiron Health; Guidepoint Global; Med Learning Group; Medscape; More Health; PER; PER; touchIME |
Consulting or Advisory Role - Ayala Pharmaceuticals; Bayer; Boehringer Ingelheim; Daiichi Sankyo; Epizyme; Karyopharm Therapeutics; Rain Therapeutics; Regeneron; Springworks Therapeutics; TYME |
Speakers' Bureau - Amgen; Boehringer Ingelheim; Karyopharm Therapeutics |
Patents, Royalties, Other Intellectual Property - GODDESS PRO Desmoid Tumor (Inst); UpToDate |
Travel, Accommodations, Expenses - Epizyme |
Other Relationship - Desmoid Tumor Research Foundation |
(OPTIONAL) Uncompensated Relationships - Athenex; Foundation Medicine |
| |
|
Stock and Other Ownership Interests - Johnson & Johnson/Janssen (I); Medtronic (I) |
Honoraria - Peerview; touchIME |
Consulting or Advisory Role - Epizyme |
Research Funding - Ayala Pharmaceuticals (Inst); Bayer; Epizyme; SpringWorks Therapeutics (Inst); SpringWorks Therapeutics (Inst) |
Travel, Accommodations, Expenses - SpringWorks Therapeutics; SpringWorks Therapeutics |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Employment - SpringWorks Therapeutics |
Stock and Other Ownership Interests - SpringWorks Therapeutics |
| |
|
Employment - SpringWorks Therapeutics |
Stock and Other Ownership Interests - SpringWorks Therapeutics |
| |
|
Employment - SpringWorks Therapeutics |
Leadership - SpringWorks Therapeutics |
Stock and Other Ownership Interests - SpringWorks Therapeutics |
| |
|
Employment - SpringWorks Therapeutics |
Stock and Other Ownership Interests - SpringWorks Therapeutics |
| |
|
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; BMS; Merck |
Research Funding - Astellas Pharma (Inst); Deciphera (Inst); EMD Serono (Inst); Epizyme (Inst); Karyopharm Therapeutics (Inst); SpringWorks Therapeutics (Inst) |
| |
|
Consulting or Advisory Role - Adcendo; Amryt Pharma; Avacta Life Sciences; Biolumina; Boehringer Ingelheim; Boxer Capital; Cogent Biosciences; Curio Science; Deciphera; Eisai; Ellipses Pharma; Exelixis; Genmab; LLX Solutions; Medpace; Merck; Moleculin Biotech; PharmaMar; Regeneron; Sanofi; SERVIER; SQZ Biotechnology; Studiecentrum voor Kernenergie (SCK CEN); Transgene; UCB |
Research Funding - Adcendo (Inst); CoBioRes NV (Inst); Eisai (Inst); G1 Therapeutics (Inst); Genmab (Inst); Merck (Inst); ONA therapeutics (Inst); PharmaMar (Inst); Sartar Therapeutics (Inst) |
| |
|
Consulting or Advisory Role - Adaptimmune; Adcendo; Boehringer Ingelheim; Daiichi Sankyo; Deciphera; Epizyme; Polaris; SpringWorks Therapeutics |
Research Funding - Agenus; Exelixis |
Travel, Accommodations, Expenses - Adaptimmune; Daiichi Sankyo; Deciphera |
| |
|
Employment - Limbguard (I) |
Leadership - Limbguard (I) |
Stock and Other Ownership Interests - Limbguard (I) |
Consulting or Advisory Role - AADi; Adaptimmune; Blueprint Medicines; Daiichi Sankyo; Deciphera; GlaxoSmithKline; NanoCarrier; SpringWorks Therapeutics |
Research Funding - AADi (Inst); Arog (Inst); Ayala Pharmaceuticals (Inst); BioAtla (Inst); Blueprint Medicines (Inst); Cogent Biosciences (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); InhibRx (Inst); NanoCarrier (Inst); Oncternal Therapeutics (Inst); Philogen (Inst); PTC Therapeutics (Inst); SpringWorks Therapeutics (Inst); TRACON Pharma (Inst); Trillium Therapeutics (Inst) |
Patents, Royalties, Other Intellectual Property - PandoNet - Limbguard (I) |
Travel, Accommodations, Expenses - Daiichi Sankyo; NanoCarrier; SpringWorks Therapeutics |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Rain Therapeutics; SpringWorks Therapeutics |
| |
|
Consulting or Advisory Role - Deciphera; Epizyme; Jazz Pharmaceuticals |
Research Funding - AADi (Inst); Advenchen Laboratories (Inst); AstraZeneca (Inst); Ayala Pharmaceuticals (Inst); Cogent Biosciences (Inst); Cornerstone Pharmaceuticals (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); InhibRx (Inst); Janssen (Inst); Mundipharma (Inst); Pfizer (Inst); Plexxikon (Inst); PTC Therapeutics (Inst); Qilu Puget Sound Biotherapeutics (Inst); SpringWorks Therapeutics (Inst) |
Patents, Royalties, Other Intellectual Property - Wolters Kluwer |
Expert Testimony - Meyers Law (Inst) |
| |
|
Stock and Other Ownership Interests - Arxeon Therapeutics (I); PathomIQ |
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Cadila Pharmaceuticals (I); EcoR1 Capital; Genome Insight; Gilead Sciences; Harbour BioMed; Mirati Therapeutics; Mundipharma; Oxford BioTherapeutics; Seagan; SpringWorks Therapeutics |
Research Funding - ADC Therapeutics (Inst); ADC Therapeutics (Inst); Advenchen Laboratories (Inst); Amgen (Inst); Astex Pharmaceuticals (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Day One Therapeutics (Inst); Dynavax Technologies (Inst); Elevation Oncology (Inst); Genome & Company (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Loxo (Inst); Moderna Therapeutics (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Plexxikon (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Vincerx Pharma (Inst) |
Travel, Accommodations, Expenses - Bayer |
| |
|
No Relationships to Disclose |